Base editing of β 0 -thalassemia mutations as a therapeutic strategy for severe β-hemoglobinopathies
- 26 November 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (826) , eadt8617
Abstract
Gene therapy has emerged as a promising curative treatment for β-hemoglobinopathies, the most common genetic disorders worldwide. However, current approved approaches still have some limitations in terms of safety and efficacy. Here, we used highly processive adenine base editor (ABE) variants to precisely correct some of the most prevalent and severe β-thalassemia–causing mutations in the β-globin–encoding HBB gene, including CD39 and IVS2-1, using NRCH-ABE8e and SpRY-ABE8e, respectively. More than 90% of editing of hematopoietic stem and progenitor cells (HSPCs) led to improved β-globin expression in their erythroid progeny and persistent correction of both β-thalassemia and sickle cell–β-thalassemia phenotypes. The safety of this strategy was confirmed in HSPCs in vitro and in vivo through the absence of gene dysregulation and any meaningful impact on the DNA mutational burden, RNA deamination, β-globin gene locus integrity, and the clonality of the HSPC graft, as assessed by RNA sequencing, whole-exome sequencing, long-read sequencing, and human HSPC transplantation in immunodeficient mice. Overall, these preclinical studies suggest that base editing–mediated gene correction may be a safe and effective strategy for treating β-hemoglobinopathies.Keywords
Funding Information
- H2020 European Research Council (865797 DITSB)
- European Cooperation in Science and Technology (CA21113)
- Agence Nationale de la Recherche (ANR-10-IAHU-01)
- Agence Nationale de la Recherche (ANR-18-IDEX-0001)
- European Comission (101057659)
This publication has 85 references indexed in Scilit:
- High-level correction of the sickle mutation is amplified in vivo during erythroid differentiationiScience, 2022
- Fetal hemoglobin in β hemoglobinopathies: Is enough too much?American Journal of Hematology, 2022
- Long noncoding RNA HBBP1 enhances γ-globin expression through the ETS transcription factor ELK1Biochemical and Biophysical Research Communications, 2021
- Increasing CRISPR Efficiency and Measuring Its Specificity in HSPCs Using a Clinically Relevant SystemMolecular Therapy - Methods & Clinical Development, 2020
- Hemoglobinopathies (structural defects in hemoglobin)2020
- A single-base change at a splice site in a β0-thalassemic gene causes abnormal RNA splicingCell, 1982
- Haemoglobin Sherwood Forest β104 (G6) Arg→ ThrFEBS Letters, 1977
- Hemoglobins Austin and Waco: Two Hemoglobins with substitutions in the α1β2 contact regionArchives of Biochemistry and Biophysics, 1977
- Hemoglobin athens-georgia, or α2β240(C6)Arg→Lys, a hemoglobin variant with an increased oxygen affinityBiochimica et Biophysica Acta (BBA) - Protein Structure, 1976
- Haemoglobin camperdown β104(G6) arginine → serineBiochimica et Biophysica Acta (BBA) - Protein Structure, 1975